GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

Phase 2
Completed
Conditions
First Posted Date
2004-11-24
Last Posted Date
2010-10-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
35
Registration Number
NCT00097409
Locations
🇺🇸

GSK Investigational Site, Madison, Wisconsin, United States

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Phase 2
Completed
Conditions
First Posted Date
2004-11-23
Last Posted Date
2015-04-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
261
Registration Number
NCT00097331
Locations
🇪🇸

GSK Investigational Site, Malaga, Spain

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2004-11-23
Last Posted Date
2017-07-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
78
Registration Number
NCT00097370
Locations
🇮🇹

GSK Investigational Site, Bologna, Emilia-Romagna, Italy

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

Phase 3
Completed
Conditions
First Posted Date
2004-10-18
Last Posted Date
2010-09-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
900
Registration Number
NCT00094367
Locations
🇺🇸

GSK Investigational Site, Milwaukee, Wisconsin, United States

HuMax-CD20 in Chronic Lymphocytic Leukemia

Phase 1
Withdrawn
Conditions
First Posted Date
2004-10-08
Last Posted Date
2015-04-21
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT00093314
Locations
🇺🇸

University of Iowa, Hospitals and Clinics, Iowa City, Iowa, United States

Major Depressive Disorder In The Elderly

Phase 3
Completed
Conditions
First Posted Date
2004-10-07
Last Posted Date
2013-09-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
364
Registration Number
NCT00093288
Locations
🇷🇺

GSK Investigational Site, Moscow, Russian Federation

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Phase 1
Withdrawn
Conditions
First Posted Date
2004-09-27
Last Posted Date
2015-04-21
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT00092274
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 3
Conditions
First Posted Date
2004-09-02
Last Posted Date
2014-01-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT00002767
Locations
🇺🇸

University of Connecticut Health Center, Farmington, Connecticut, United States

🇺🇸

Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

🇺🇸

Creighton University Cancer Center, Omaha, Nebraska, United States

and more 24 locations

Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults

Phase 1
Completed
Conditions
First Posted Date
2004-08-26
Last Posted Date
2006-02-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
50
Registration Number
NCT00090077
Locations
🇺🇸

GSK Clinical Trials Call Center, Seattle, Washington, United States

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

First Posted Date
2004-08-26
Last Posted Date
2017-02-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4844
Registration Number
NCT00090103
Locations

GSK Investigational Site

© Copyright 2024. All Rights Reserved by MedPath